<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04528836</url>
  </required_header>
  <id_info>
    <org_study_id>NAV-1001</org_study_id>
    <nct_id>NCT04528836</nct_id>
  </id_info>
  <brief_title>First-in-Human Study of the SHP2 Inhibitor BBP-398 in Patients With Advanced Solid Tumors</brief_title>
  <official_title>A Phase 1/1B First-in-Human Study of the SHP2 Inhibitor BBP-398 (Formerly Known as IACS-15509) in Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Navire Pharma Inc., a BridgeBio company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Navire Pharma Inc., a BridgeBio company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A first-in-human study is to evaluate the safety, tolerability and maximum tolerated dose&#xD;
      (MTD) and establish the recommended phase 2 dose (RP2D) of BBP-398, a SHP2 inhibitor, in&#xD;
      patients with advanced solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The first-in-human (FIH) study of BBP-398 will be an open-label, sequential-cohort,&#xD;
      non-randomized, Phase 1/1B study utilizing BOIN dose escalation followed by an expansion&#xD;
      phase in patients with MAPK pathway- or RTK-driven advanced solid tumors. The primary&#xD;
      objective is to determine safety and tolerability of BBP-398, the MTD and RP2D. The secondary&#xD;
      objectives are to assess the pharmacokinetic (PK) and pharmacodynamic (PD) profile,&#xD;
      preliminary anti-tumor activity, objective response rate (ORR, complete response + partial&#xD;
      response rate) and the duration of response (DoR) of BBP-398. The exploratory objective is to&#xD;
      assess predictive biomarkers of response.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 12, 2020</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determination of Maximum Tolerated Dose (MTD) of BBP-398.</measure>
    <time_frame>Completion of 1 Cycle ( 28 days)</time_frame>
    <description>The MTD will be based on DLT.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determination of anti-tumor activity of BBP-398</measure>
    <time_frame>Completion of 1 Cycle ( 28 days)</time_frame>
    <description>Anti-tumor activity will be defined by objective response rate (ORR2, complete response + partial response rate) and duration of response (DOR3)</description>
  </secondary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Tumor, Solid</condition>
  <arm_group>
    <arm_group_label>Dose Escalation Level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Level 1 oral capsules. Each treatment cycle will be 28 days in duration with BBP-398 administered, once daily (QD).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Escalation Level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Level 2 oral capsules. Each treatment cycle will be 28 days in duration with BBP-398 administered, once daily (QD).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Escalation Level 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Level 3 oral capsules. Each treatment cycle will be 28 days in duration with BBP-398 administered, once daily (QD).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Escalation Level 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Level 4 oral capsules. Each treatment cycle will be 28 days in duration with BBP-398 administered, once daily (QD).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Escalation Level 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Level 5 oral capsules. Each treatment cycle will be 28 days in duration with BBP-398 administered, once daily (QD).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Escalation Level 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Level 6 oral capsules. Each treatment cycle will be 28 days in duration with BBP-398 administered, once daily (QD).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Expansion Cohort A: Advanced KRAS G12C NSCLC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MTD/RP2D defined dose. Oral capsules Each treatment cycle will be 28 days in duration with BBP-398 administered, once daily (QD)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Expansion Cohort B: Advanced KRAS G12C non-NSCLC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MTD/RP2D defined dose. Oral capsules Each treatment cycle will be 28 days in duration with BBP-398 administered, once daily (QD)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Expansion Cohort C: Advanced solid tumor with other MAPK-</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MTD/RP2D defined dose. Oral capsules Each treatment cycle will be 28 days in duration with BBP-398 administered, once daily (QD)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Expansion Cohort D: Advanced EGFR-mutant NSCLC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MTD/RP2D defined dose. Oral capsules Each treatment cycle will be 28 days in duration with BBP-398 administered, once daily (QD)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BBP-398 (Formerly Known as IACS-15509)</intervention_name>
    <description>oral capsules</description>
    <arm_group_label>Dose Escalation Level 1</arm_group_label>
    <arm_group_label>Dose Escalation Level 2</arm_group_label>
    <arm_group_label>Dose Escalation Level 3</arm_group_label>
    <arm_group_label>Dose Escalation Level 4</arm_group_label>
    <arm_group_label>Dose Escalation Level 5</arm_group_label>
    <arm_group_label>Dose Escalation Level 6</arm_group_label>
    <arm_group_label>Expansion Cohort A: Advanced KRAS G12C NSCLC</arm_group_label>
    <arm_group_label>Expansion Cohort B: Advanced KRAS G12C non-NSCLC</arm_group_label>
    <arm_group_label>Expansion Cohort C: Advanced solid tumor with other MAPK-</arm_group_label>
    <arm_group_label>Expansion Cohort D: Advanced EGFR-mutant NSCLC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion&#xD;
&#xD;
          1. Male and non-pregnant females &gt;18 years old.&#xD;
&#xD;
          2. Patients must have a diagnosis of advanced (primary or recurrent) or metastatic solid&#xD;
             tumor with MAPK-pathway alterations (excluding BRAF V600X) as assessed by clinically&#xD;
             validated and/or FDA-approved molecular diagnostic and no available standard of care&#xD;
             or curative therapies (MAPK-pathway alterations include, for example KRASG12C mutant,&#xD;
             EGFR-mutant; see Appendix 1).&#xD;
&#xD;
          3. Dose expansion only: Patients with the following genomically defined tumor types will&#xD;
             be recruited.&#xD;
&#xD;
          4. Patients must have measurable disease by RECIST v1.1.&#xD;
&#xD;
          5. Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status&#xD;
             (PS) 0-2.&#xD;
&#xD;
          6. Patients must have adequate organ function.&#xD;
&#xD;
          7. Patients must be â‰¥3 weeks beyond treatment with any chemotherapy or other&#xD;
             investigational therapy.&#xD;
&#xD;
          8. Women of childbearing potential (WOCBP) MUST have a negative serum or urine HCG test.&#xD;
&#xD;
          9. Patients must have the ability to understand and the willingness to sign a written&#xD;
             informed consent document prior to the initiation of the study and any study&#xD;
             procedures.&#xD;
&#xD;
         10. Patients must be willing and able to comply with the scheduled visits, treatment plan,&#xD;
             laboratory tests and other specified study procedures.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          1. Patients with known active Hepatitis B, Hepatitis C infection, or HIV infection.&#xD;
&#xD;
          2. Patients with active infection requiring intravenous (IV) antibiotics or other&#xD;
             uncontrolled intercurrent illness requiring hospitalization. Minor infections are&#xD;
             allowed.&#xD;
&#xD;
          3. Patients with a history of CVA, myocardial infarction or unstable angina within the&#xD;
             previous 6 months before starting therapy.&#xD;
&#xD;
          4. Patients with clinically significant cardiac disease.&#xD;
&#xD;
          5. Patients with a history of LVEF &lt;50% within the previous 12 months.&#xD;
&#xD;
          6. Patients with a history of retinal vein occlusion (RVO).&#xD;
&#xD;
          7. Patients with tumors harboring known activating mutations in BRAF V600X, PTPN11 (SHP2)&#xD;
             or RAS Q61.&#xD;
&#xD;
          8. Patients with a known additional malignancy that is progressing or requires active&#xD;
             treatment. Exceptions include basal cell carcinoma of the skin, squamous cell&#xD;
             carcinoma of the skin that has undergone potentially curative therapy or in situ&#xD;
             cervical cancer.&#xD;
&#xD;
          9. Patients with known central nervous system (CNS) tumors.&#xD;
&#xD;
         10. Patients with known active CNS metastases and/or carcinomatous meningitis. Patients&#xD;
             with previously treated brain metastases may participate provided they are stable.&#xD;
&#xD;
         11. Patients who have undergone major surgery within 4 weeks prior to study enrollment.&#xD;
&#xD;
         12. Patients who have previously received a SHP2 inhibitor.&#xD;
&#xD;
         13. Patients with inability to swallow oral medications.&#xD;
&#xD;
         14. Patients should not have gastrointestinal illness that would preclude the absorption&#xD;
             of an oral agent.&#xD;
&#xD;
         15. Patients on dialysis.&#xD;
&#xD;
         16. Female patients who are pregnant, planning to become pregnant, or who are&#xD;
             breastfeeding.&#xD;
&#xD;
         17. Any patient, who in the opinion of the investigator, is likely to be unable to comply&#xD;
             with the study procedures.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carl Dambkowski, MD, VP Clinical Strategy, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Navire Pharma Inc., a BridgeBio company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vaeling Clinical Operations Lead</last_name>
    <phone>14082031726</phone>
    <email>vaeling.miller@bridgebio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>720-754-2610</phone>
    </contact>
    <investigator>
      <last_name>Gerald Falchook, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77096</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator askMDAnderson</last_name>
      <phone>877-632-6789</phone>
    </contact>
    <investigator>
      <last_name>David Hong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NEXT Oncology</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>210-589-9500</phone>
    </contact>
    <investigator>
      <last_name>Karim Raghad, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer Institute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>888-424-2100</phone>
      <email>cancerinfo@hci.utah.edu</email>
    </contact>
    <investigator>
      <last_name>Ignacio Garrido-Laguna, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 27, 2020</study_first_submitted>
  <study_first_submitted_qc>August 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 27, 2020</study_first_posted>
  <last_update_submitted>September 2, 2021</last_update_submitted>
  <last_update_submitted_qc>September 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cancer</keyword>
  <keyword>MAPK-pathway alterations</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

